Compare Incyte Corporation (INCY) vs Vanguard Growth Index Fund ETF (VUG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Vanguard Growth Index Fund ETF — how do they compare? Incyte Corporation trades at $120.8 (market cap $24.54B), while Vanguard Growth Index Fund ETF trades at $88.97. The key difference: Vanguard Growth Index Fund ETF is trading nearer its 52-week high, Incyte Corporation nearer its low. Which is the better fit depends on your goals.
| INCY | VUG | |
|---|---|---|
Market Cap | $24.54B | — |
Sector | Health | Sector/Thematic |
52-Week High | $129.93 | $90.29 |
52-Week Low | $81.61 | $70.00 |
Enterprise Value | $20.04B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte Corporation (INCY) trades at $120.93, down 0.51% on the day, near its 52-week high. The stock shows strong fundamental momentum with Q2 2026 EPS beating estimates at $3.09 versus $2.15 expected, driven by robust Jakafi and Opzelura sales. Revenue growth accelerated to $5.14 billion in 2025, with net income margin expanding to 27.71%. Technical indicators signal a bullish trend with moving averages supporting upside, while oscillators remain neutral.
Outlook remains positive given raised 2026 revenue guidance and recent EU approval for Opzelura, though risks include competitive pressures and reliance on key products. Analyst consensus is bullish with a $122.82 price target, implying modest upside from current levels amid solid institutional ownership trends.
Vanguard Growth ETF (VUG) trades at $89.01, down 0.19% today, with a bullish technical signal from moving averages but overbought RSI readings. Recent news highlights strong institutional buying, with multiple firms increasing stakes by over 500% in Q2 2026 (Defense World, August 2026). The ETF focuses on large-cap growth stocks, benefiting from exposure to tech leaders like Microsoft.
The outlook remains positive given institutional accumulation and growth stock momentum, though high RSI levels suggest near-term consolidation risk. Key risks include market volatility and sector concentration, but long-term growth exposure aligns with bullish analyst sentiment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Vanguard Growth Index Fund ETF
VUG is an index-based ETF that tracks the CRSP US Large Cap Growth Index, providing concentrated exposure to the largest and fastest-growing companies in the United States. It focuses on stocks with high growth potential across tech, communication, and consumer sectors, serving as a low-cost, high-conviction core holding for long-term capital appreciation.
Read more on VUG →
